HUTCHMED Licenses KRAS-EGFR ATTC HMPL-A830 to GSK in Deal Worth Up to $1.295 Billion
China-based biopharmaceutical company HUTCHMED has entered into an exclusive global licensing and development agreement with GSK for HMPL-A830, a potentially first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in a transaction that could…